- Quotient Sciences and Biorasi have formed a strategic partnership to provide fully integrated early-phase clinical trial solutions, combining clinical development expertise with global patient recruitment capabilities.
- The partnership offers a single-provider model for first-in-human (FIH) to proof-of-concept (POC) programs, including options for unified contracts, protocols, and regulatory submissions.
Quotient Sciences has announced a strategic partnership with Biorasi to deliver fully integrated early phase clinical trial solutions. The collaboration combines Quotient’s early clinical development expertise with Biorasi’s global patient recruitment network, targeting a simplified pathway from Investigational New Drug (IND) to proof-of-concept (POC).
The partnership is designed to support first-in-human (FIH) Phase I/IIa trials, with seamless transitions from healthy volunteers to patient cohorts. Sponsors will have access to Quotient Sciences’ clinical pharmacology facilities in Miami (US) and Nottingham (UK), featuring 230 beds and a large database of trial participants. Biorasi contributes a wide-reaching recruitment network covering multiple therapeutic areas, including dermatology, neurology, nephrology, and cell therapy.
Under the agreement, sponsors can engage a single provider for their early phase programs, reducing outsourcing complexity. The model allows unified contracting, protocol design, and regulatory submissions, intended to accelerate development timelines and integrate patient assessments and biomarker studies efficiently.
“This partnership reflects our 35-year commitment to helping customers accelerate drug development to Proof of Concept by reducing complexity and breaking down traditional barriers. By combining Quotient’s clinical expertise with Biorasi’s global patient access network, we enable Sponsors to efficiently conduct early-phase studies under a single operational and contracting model, while maintaining the highest standards of clinical research and data quality.”
Thierry Van Nieuwenhove, CEO of Quotient Sciences
The collaboration builds on Quotient’s Translational Pharmaceutics® approach, which integrates formulation development, drug product manufacturing, and clinical testing. This strategy aims to save up to 12 months in development timelines while expanding opportunities for complementary CDMO services such as pharmacy compounding, drug product manufacturing, data sciences, and regulatory support.
